NCT02052687View on ClinicalTrials.gov

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LFX453

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Healthy
Interventions
DRUG

LFX453 H1

LFX453 high dose cream 1

DRUG

LFX453 L1

LFX453 low dose cream 1

DRUG

LFX453 H2

LFX453 high dose cream 2

DRUG

LFX453 L2

LFX453 low dose cream 2

DRUG

Imiquimod

Imiquimod cream

DRUG

Placebo 1

Placebo cream 1

DRUG

Placebo 2

Placebo cream 2

Trial Locations (1)

CF484DR

Novartis Investigative Site, Mid Glamorgan

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY